Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03006705
Recruitment Status : Recruiting
First Posted : December 30, 2016
Last Update Posted : October 2, 2018
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Ono Pharmaceutical Co. Ltd

Brief Summary:
The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.

Condition or disease Intervention/treatment Phase
Gastric Cancer Drug: Nivolumab Drug: Tegafur-gimeracil-oteracil potassium Drug: Oxaliplatin Drug: Capecitabine Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 700 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy
Study Start Date : January 2017
Estimated Primary Completion Date : June 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Nivolumab group

Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).

Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.

S-1 therapy(maximum 1 year):

Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off

CapeOX Therapy(maximum 6 months):

Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.

Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.

Drug: Nivolumab
Other Names:
  • BMS-936558
  • ONO-4538
  • MDX-1106

Drug: Tegafur-gimeracil-oteracil potassium
Drug: Oxaliplatin
Drug: Capecitabine
Placebo Comparator: Placebo group

Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year).

Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.

S-1 therapy(maximum 1 year):

Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off

CapeOX Therapy(maximum 6 months):

Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.

Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.

Drug: Tegafur-gimeracil-oteracil potassium
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Placebo



Primary Outcome Measures :
  1. Relapse-free survival (RFS) [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 5 years ]
  2. 3-year OS rate [ Time Frame: 3 years ]
  3. 5-year OS rate [ Time Frame: 5 years ]
  4. 3-year RFS rate [ Time Frame: 3 years ]
  5. 5-year RFS rate [ Time Frame: 5 years ]
  6. Safety will be analyzed through the incidence of adverse events, serious adverse events [ Time Frame: Up to 28 days from last dose ]
  7. Safety will be analyzed through the incidence of laboratory abnormalities [ Time Frame: Up to 28 days from last dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically confirmed adenocarcinoma of the stomach
  • Patients without a remnant cancer (R0) who have undergone gastrectomy
  • Gastric carcinoma according to the stage classification of AJCC/UICC TNM Classification, 7th Edition on the basis of overall postoperative findings
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1

Exclusion Criteria:

  • Patients who have received non-surgical treatment (e.g., radiotherapy, chemotherapy, hormone therapy) for gastric cancer
  • Multiple primary cancers
  • A current or past history of severe hypersensitivity to any other antibody products
  • Any concurrent autoimmune disease or past history of chronic or recurrent autoimmune disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03006705


Contacts
Layout table for location contacts
Contact: Ono Pharmaceutical Co. Ltd Corporate Communications y.tani@ono.co.jp

Locations
Show Show 103 study locations
Sponsors and Collaborators
Ono Pharmaceutical Co. Ltd
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Mitsunobu Tanimoto Ono Pharmaceutical Co. Ltd

Layout table for additonal information
Responsible Party: Ono Pharmaceutical Co. Ltd
ClinicalTrials.gov Identifier: NCT03006705    
Other Study ID Numbers: ONO-4538-38
First Posted: December 30, 2016    Key Record Dates
Last Update Posted: October 2, 2018
Last Verified: September 2018
Keywords provided by Ono Pharmaceutical Co. Ltd:
ONO-4538,BMS-936558,Nivolumab,gastric,adjuvant,S-1,CapeOX
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Nivolumab
Capecitabine
Oxaliplatin
Tegafur
Antineoplastic Agents, Immunological
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action